Medtronic PLC said late Thursday that it plans to buy the Israel-based Mazor Robotics Ltd. for $1.64 billion in cash.
Mazor stock is up 7.5% and Medtronic fell less than 0.1% after hours. The S&P 500 index closed up 0.8%. Medtronic, a medical technology maker, said it would pay $58.50 for each American Depository Share of Mazor, which makes robotic guidance systems that are applied to medical tech.
“The Mazor team and product portfolio’s full integration into Medtronic will maximize our impact globally through Medtronic’s channels, advance our systems’ leadership position in the marketplace, and drive the realization of our vision to heal through innovation,” said Mazor CEO Ori Hadomi.
The acquisition is expected to close during Medtronic’s third fiscal quarter, which ends Jan. 25, 2019.
By Max A. Cherney
Source: MarketWatch
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
